CGON vs NEM · rev $4.0M vs P/E 14, rev $13.43B
CG Oncology, Inc. Common stock (CGON) versus Newmont Goldcorp Corp (NEM) — a side-by-side from cached financials, not a winner call.
CG Oncology, Inc. Common stock (CGON) is a biotechnology company listed on US.
Newmont Goldcorp Corp (NEM) is a gold company listed on NYSE.
Latest reported CGON revenue for 2025-12-31 was $4.0M. Net income was -$161.0M. Revenue was up 254.7% from 2024-12-31 to 2025-12-31. CGON currently screens at market cap $4.74B.
Latest reported NEM revenue for 2026-06-30 was $13.43B. Net income was $5.46B. Revenue was up 83.7% from 2026-03-31 to 2026-06-30. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
CGON currently screens at market cap $4.74B. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
Not investment advice. Open the CGON and NEM stock pages for the full models.
Not investment advice.